📰 Immunization Practices News
Page 25 - Immunization Practices News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunization Practices. Real-time updates on events, politics, business and more.
October 26, 2023
Bavarian Nordic said on Wednesday a CDC panel has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox.
October 26, 2023
Drug companies are marketing RSV vaccines to US seniors, when it's infants who need them the most.
October 26, 2023
CDC vaccine advisory group recommends two-dose mpox vaccine for people 18 and older at higher risk of infection.
October 26, 2023
And ACIP also recommended use of the new pentavalent meningitis shot
October 26, 2023
Men who have sex with men and others who are at high risk of mpox infection should get two doses of the Jynneos vaccine, even now that the recent public health emergency in the United States has passed, according to an independent panel of experts that advises the US Centers for Disease Control and Prevention on its vaccine decisions.
October 26, 2023
FDA has granted Pfizers meningitis vaccine full approval and the CDC Advisory Committee on Immunization Practices has recommended it for use.
October 26, 2023
Men who have sex with men and others who are at high risk of mpox infection should get two doses of the Jynneos vaccine, even now that the recent public health emergency in the United States has passed, according to an independent panel of experts that advises the US Centers for Disease Control and Prevention on its vaccine decisions.
October 26, 2023
The CDC’s Advisory Committee on Immunization Practices has voted in favor of routine use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for the prevention of mpox disease.
October 25, 2023
GSK's Arexvy shows positive preliminary results from phase III trial
October 25, 2023
An RSV vaccine approved for use in older adults could help protect people as young as 50 who have certain underlying medical conditions and are at increased risk from the respiratory virus, according to preliminary data released by vaccine maker GSK.